Pharma women rank among world's most powerful; FDA asks for more data on appendicitis test;

> Top executives from several leading pharma companies made Forbes' "The World's Most Powerful Women" list. The annual feature ranks women based on visibility in the media and organization or country size. This year's list includes Johnson and Johnson's Sherilyn McCoy (65th), GlaxoSmithKline's Deirdre Connelly (73rd), Pfizer's Amy Schulman (80th), and Melanie Healey of Proctor & Gamble (83rd). Report

> RXi Pharmaceuticals' CFO Stephen DiPalma has resigned to "pursue other opportunities." Report

> The FDA has requested additional information on AspenBio Pharma's application for its AppyScore test, the first blood-based test designed to aid in the diagnosis of human appendicitis. Release

> With less than 9 percent of Medarex's outstanding shares tendered, Bristol-Myers Squibb is extending its offer for Medarex until August 26. Report

Pharma News

> Is Teva on Shire's trail? The rumors are flying thick and fast enough that analysts are theorizing about Shire's potential defensive moves. Report

> How often do accusations of over-touting a drug land a pharma CEO in criminal court? Not often. No wonder, then, that so many eyes are turned to a San Francisco court this week where the ex-chief of InterMune faces federal prosecution. Report

> In the wake of new safety data on Merck's human papillomavirus vaccine, both FDA and the Centers for Disease Control and Prevention have issued a statement supporting the product. Report

> Should Amgen and Johnson & Johnson be worried? Medicare is convening a group of experts for advice on using the companies' blockbuster anemia drugs. The Centers for Medicare & Medicaid Services wants the group to review the drugs--Procrit, Aranesp and Epogen--and their use in chronic kidney disease. Report

And Finally...  Good news for people fearful of needles: researchers have designed a painless patch (photo) filled with 'microneedles' that may someday render hypodermic needles--as well as annual flu shots--a thing of the past. Report

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.